Light Touch Technology raises $3.4M for blood-free glucose sensor
What's the deal? Osaka-based Light Touch TechnologyDealroom has a profile for this one. Try Dealroom → (LTT) has raised ¥500M (roughly $3.4M) in a Series B extension round to develop a non-invasive blood glucose sensor that measures levels in about five seconds — just by touching a fingertip to the device. The round was backed by TamronDealroom has a profile for this one. Try Dealroom →, JMTC Capital, Hiroshima Venture CapitalDealroom has a profile for this one. Try Dealroom →, and BP Capital, alongside a Kyoto Prefecture subsidy and a loan from Kiyo Bank. Total funding to date now stands at roughly ¥1.2B (~$8.2M).
Founded in 2017, LTT says it has built a high-brightness infrared laser approximately one billion times brighter than conventional light sources, enabling what it calls the world's first non-invasive blood glucose measurement. Data transmits wirelessly to a smartphone in real time.
Why now? More than 500 million people worldwide live with diabetes, most of whom must prick their fingers four to five times a day to monitor blood sugar — a painful, stressful routine that carries infection risk. The global diabetic population is still growing, making less invasive monitoring an urgent medical priority.
The fresh capital will fund clinical performance trials and production engineering aimed at regulatory approval and commercial launch.
What could go wrong? Non-invasive glucose monitoring is a notoriously difficult problem. Dozens of attempts over the past two decades — including high-profile efforts by major tech companies — have failed to achieve the accuracy regulators demand. LTT still needs to clear clinical trials and secure regulatory approval, processes that can take years and carry no guarantee of success.
Competition is also intensifying. Continuous glucose monitors from Dexcom and Abbott already reduce the need for fingerstick tests, and several other startups are pursuing truly non-invasive approaches.
The signal: LTT's backer mix — spanning optics manufacturer Tamron, regional fund Hiroshima Venture Capital, and corporate investor JMTC Capital — reflects a pattern of strategic, rather than purely financial, conviction behind deep-tech health hardware in Japan. The company remains at Dealroom's "early growth" stage with roughly $8.2M raised in total, a modest sum for a medtech startup pursuing regulatory clearance, suggesting it will need significantly larger rounds to fund the clinical trials and manufacturing scale required to compete in a market where late-growth incumbents like Dexcom have already set high bars for accuracy and trust.
Read more: prtimes.jp
